Identified a Novel Biomarker, Sarcoglycan Beta Correlated with Poor Prognosis in Glioblastoma Multiforme

Abstract Background: Glioblastoma multiforme (GBM) is the most aggressive and lethal in glioma. The most common chemotherapy is temozolomide. However, drug resistance increased patient recurrence and mortality rates. Sarcoglycan beta (SGCB) is a transmembrane protein involved in the dystrophin-glycoprotein complex of muscle fibers and affects tumor progression in several cancers. Aim: We found that SGCB is a potential biomarker in the development of GBM therapeutics. The study aimed to investigate the role and function of SGCB in GBM. Methods: We collected the mRNA expression of SGCB from The Cancer Genome Atlas databases for bioinformatics analyses, including the expression difference, Kaplan–Meier survival, and Cox survival analysis. Next, the single-cell sequencing databases were analyzed to investigate the role of SGCB in glioma. Then, the Gene Set Enrichment Analysis was performed to identify the signaling pathways of SGCB in glioma. Finally, to identify the effect of SGCB on the tumor microenvironment of GBM, we used CIBERSORT analysis. Results: It was shown that SGCB was highly expressed in tumor tissue compared with the normal group and was correlated with poor prognosis. Moreover, SGCB is mainly expressed in the tumor component. We also found that SGCB was correlated with cell cycle, DNA duplication, and the regulated release of protein in glioma. CIBERSORT analyses revealed that high levels of SGCB affected several immune cells in the tumor microenvironment. Conclusion: These data showed that SGCB was expected to serve as an independent prognosis biomarker in GBM. This identification may provide new possibilities for targeted therapies.